Richmond Archives · BioBuzz

Loading …

Phlow Corp. Closes $20 Million Series A Financing to Further Essential Medicines Research and Development Programs and Advanced Manufacturing Initiatives

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-75x75.png 75w" data-src="https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-300x300.png" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-300x300.png" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-300x300.png 300w, https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-150x150.png 150w, https://biobuzz.io/wp-content/uploads/2021/02/phlow-corp-logo-75x75.png 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : February 16, 2021February 17, 2021 Published by : BioBuzz Media

Phlow Corp. Closes $20 Million Series A Financing to Further Essential Medicines Research and Development Programs and Advanced Manufacturing Initiatives Pioneering essential medicines company seeks to actively accelerate U.S. manufacturing [….]

5 Questions with John Newby, CEO, Virginia Bio

<img width="300" height="300" alt="" data-srcset="https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-75x75.jpg 75w" data-src="https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-300x300.jpg" data-sizes="(max-width: 300px) 100vw, 300px" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload lazyload" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" /><noscript><img width="300" height="300" src="https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-300x300.jpg" class="attachment-biobuzz-medium size-biobuzz-medium wp-post-image lazyload" alt="" srcset="https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-300x300.jpg 300w, https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-150x150.jpg 150w, https://biobuzz.io/wp-content/uploads/2020/10/John-Newby-75x75.jpg 75w" sizes="(max-width: 300px) 100vw, 300px" />

Published on : October 27, 2020October 27, 2020 Published by : Andy Eckert

John Newby is the CEO at Virginia Bio, the statewide non-profit trade association for the life science industry. Approximately 300 companies spanning biopharmaceuticals, medical devices, med tech, diagnostics, digital health, bioinformatics, agriculture, and industrial bio and related fields are based in Virginia, mainly clustered around research universities and medical institutions. Virginia Bio is the sole state affiliate and works closely with key national industry organizations BIO, AdvaMed, MDMA, PhRMA and We Work for Health.